Analysts’ Ratings for Omeros and Peers in March 2018
By Kenneth SmithMar. 29 2018, Updated 2:48 p.m. ET
Company overview
Omeros (OMER) is a commercial biopharmaceutical company. Its product, Omidria, is marketed in the United States for use in cataract surgery.
Analysts’ recommendations
Of the five analysts covering Omeros in March 2018, three recommended “buy” or a higher rating, and two recommended “hold.” The stock’s mean rating was 2.2, and its target price was $37.17.
Peer ratings
Of the 21 analysts covering Abbott Laboratories (ABT) in March 2018, seven recommended “strong buy,” ten recommended “buy,” and four recommended “hold.” The stock’s mean rating was 1.9, and its target price was $68.22.
Of the 22 analysts covering Eli Lilly (LLY) in March 2018, 13 recommended “buy” or a higher rating, seven analysts recommended “hold,” and two recommended “sell.” The stock’s mean rating was 2.2, and its target price was $91.29.
Of the eight analysts covering Novavax (NVAX) in March 2018, two recommended “strong buy,” one recommended “buy,” four recommended “hold,” and one recommended “sell.” The stock’s mean rating was 2.5, and its target price was $3.83. In the next part of this series, we’ll look at Omeros’s research pipeline.
